Antiparkinsonian activity of L‐propyl‐L‐leucyl‐glycinamide or melanocyte‐inhibiting factor in MPTP‐treated common marmosets
Identifieur interne : 000355 ( Main/Exploration ); précédent : 000354; suivant : 000356Antiparkinsonian activity of L‐propyl‐L‐leucyl‐glycinamide or melanocyte‐inhibiting factor in MPTP‐treated common marmosets
Auteurs : Regina Katzenschlager [Royaume-Uni, Autriche] ; Michael J. Jackson [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; Kim Stockwell [Royaume-Uni] ; Kayhan A. Tayarani-Binazir [Royaume-Uni] ; Mohammed Zubair [Royaume-Uni] ; Lance A. Smith [Royaume-Uni] ; Peter Jenner [Royaume-Uni] ; Andrew J. Lees [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2007-04-15.
English descriptors
Abstract
The neuropeptide melanocyte‐inhibiting factor (MIF) or L‐propyl‐L‐leucyl‐glycinamide (PLG) has been reported in some studies to improve the motor signs of Parkinson's disease (PD) and in rodent models of PD. In this study of oral and intravenous MIF in N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐lesioned marmosets, a wide range of doses of MIF administered alone (0.25, 1, 2, 5, 10, 20 mg/kg orally) did not increase locomotor activity, relieve motor disability, or induce dyskinesias. When MIF (1.0 and 5.0 mg/kg orally or 10 and 20 mg/kg intravenously) was administered concomitantly with levodopa/benserazide, no significant differences in motor function or dyskinesias were observed compared with levodopa/benserazide alone. The results of this first study of MIF in the marmoset MPTP model provide no encouragement for the reinvestigation of MIF in the clinical management of the motor signs of PD. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21256
Affiliations:
- Autriche, Royaume-Uni
- Angleterre, Grand Londres, Vienne (Autriche)
- Londres, Vienne (Autriche)
- King's College de Londres, University College de Londres
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000019
- to stream Istex, to step Curation: 000013
- to stream Istex, to step Checkpoint: 000137
- to stream Main, to step Merge: 000356
- to stream Main, to step Curation: 000355
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antiparkinsonian activity of L‐propyl‐L‐leucyl‐glycinamide or melanocyte‐inhibiting factor in MPTP‐treated common marmosets</title><author><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name></author><author><name sortKey="Jackson, Michael J" sort="Jackson, Michael J" uniqKey="Jackson M" first="Michael J." last="Jackson">Michael J. Jackson</name></author><author><name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name></author><author><name sortKey="Stockwell, Kim" sort="Stockwell, Kim" uniqKey="Stockwell K" first="Kim" last="Stockwell">Kim Stockwell</name></author><author><name sortKey="Tayarani Inazir, Kayhan A" sort="Tayarani Inazir, Kayhan A" uniqKey="Tayarani Inazir K" first="Kayhan A." last="Tayarani-Binazir">Kayhan A. Tayarani-Binazir</name></author><author><name sortKey="Zubair, Mohammed" sort="Zubair, Mohammed" uniqKey="Zubair M" first="Mohammed" last="Zubair">Mohammed Zubair</name></author><author><name sortKey="Smith, Lance A" sort="Smith, Lance A" uniqKey="Smith L" first="Lance A." last="Smith">Lance A. Smith</name></author><author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name></author><author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew J. Lees</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:3A0D5F157B0A593D17D43EB7E889F5189630C0AD</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21256</idno><idno type="url">https://api.istex.fr/document/3A0D5F157B0A593D17D43EB7E889F5189630C0AD/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000019</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000019</idno><idno type="wicri:Area/Istex/Curation">000013</idno><idno type="wicri:Area/Istex/Checkpoint">000137</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000137</idno><idno type="wicri:doubleKey">0885-3185:2007:Katzenschlager R:antiparkinsonian:activity:of</idno><idno type="wicri:Area/Main/Merge">000356</idno><idno type="wicri:Area/Main/Curation">000355</idno><idno type="wicri:Area/Main/Exploration">000355</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Antiparkinsonian activity of L‐propyl‐L‐leucyl‐glycinamide or melanocyte‐inhibiting factor in MPTP‐treated common marmosets</title><author><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Reta Lila Weston Institute of Neurological Studies, University College London, United Kingdom and National Hospital for Neurology and Neurosurgery, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName type="university">University College de Londres</orgName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, Donauspital/SMZ‐Ost, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Jackson, Michael J" sort="Jackson, Michael J" uniqKey="Jackson M" first="Michael J." last="Jackson">Michael J. Jackson</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, King's College London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName type="university">King's College de Londres</orgName></affiliation></author><author><name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, King's College London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName type="university">King's College de Londres</orgName></affiliation></author><author><name sortKey="Stockwell, Kim" sort="Stockwell, Kim" uniqKey="Stockwell K" first="Kim" last="Stockwell">Kim Stockwell</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, King's College London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName type="university">King's College de Londres</orgName></affiliation></author><author><name sortKey="Tayarani Inazir, Kayhan A" sort="Tayarani Inazir, Kayhan A" uniqKey="Tayarani Inazir K" first="Kayhan A." last="Tayarani-Binazir">Kayhan A. Tayarani-Binazir</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, King's College London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName type="university">King's College de Londres</orgName></affiliation></author><author><name sortKey="Zubair, Mohammed" sort="Zubair, Mohammed" uniqKey="Zubair M" first="Mohammed" last="Zubair">Mohammed Zubair</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, King's College London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName type="university">King's College de Londres</orgName></affiliation></author><author><name sortKey="Smith, Lance A" sort="Smith, Lance A" uniqKey="Smith L" first="Lance A." last="Smith">Lance A. Smith</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, King's College London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName type="university">King's College de Londres</orgName></affiliation></author><author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, King's College London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName type="university">King's College de Londres</orgName></affiliation></author><author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew J. Lees</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Reta Lila Weston Institute of Neurological Studies, University College London, United Kingdom and National Hospital for Neurology and Neurosurgery, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName type="university">University College de Londres</orgName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Reta Lila Weston Institute of Neurological Studies, Windeyer Building, 46 Cleveland Street, London W1 T 4JF</wicri:regionArea><wicri:noRegion>London W1 T 4JF</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-04-15">2007-04-15</date><biblScope unit="volume">22</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="715">715</biblScope><biblScope unit="page" to="719">719</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">3A0D5F157B0A593D17D43EB7E889F5189630C0AD</idno><idno type="DOI">10.1002/mds.21256</idno><idno type="ArticleID">MDS21256</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>dyskinesia</term><term>marmoset</term><term>melanocyte‐inhibiting factor (MIF)</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The neuropeptide melanocyte‐inhibiting factor (MIF) or L‐propyl‐L‐leucyl‐glycinamide (PLG) has been reported in some studies to improve the motor signs of Parkinson's disease (PD) and in rodent models of PD. In this study of oral and intravenous MIF in N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐lesioned marmosets, a wide range of doses of MIF administered alone (0.25, 1, 2, 5, 10, 20 mg/kg orally) did not increase locomotor activity, relieve motor disability, or induce dyskinesias. When MIF (1.0 and 5.0 mg/kg orally or 10 and 20 mg/kg intravenously) was administered concomitantly with levodopa/benserazide, no significant differences in motor function or dyskinesias were observed compared with levodopa/benserazide alone. The results of this first study of MIF in the marmoset MPTP model provide no encouragement for the reinvestigation of MIF in the clinical management of the motor signs of PD. © 2007 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Autriche</li><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li><li>Vienne (Autriche)</li></region><settlement><li>Londres</li><li>Vienne (Autriche)</li></settlement><orgName><li>King's College de Londres</li><li>University College de Londres</li></orgName></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name></region><name sortKey="Jackson, Michael J" sort="Jackson, Michael J" uniqKey="Jackson M" first="Michael J." last="Jackson">Michael J. Jackson</name><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew J. Lees</name><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew J. Lees</name><name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name><name sortKey="Smith, Lance A" sort="Smith, Lance A" uniqKey="Smith L" first="Lance A." last="Smith">Lance A. Smith</name><name sortKey="Stockwell, Kim" sort="Stockwell, Kim" uniqKey="Stockwell K" first="Kim" last="Stockwell">Kim Stockwell</name><name sortKey="Tayarani Inazir, Kayhan A" sort="Tayarani Inazir, Kayhan A" uniqKey="Tayarani Inazir K" first="Kayhan A." last="Tayarani-Binazir">Kayhan A. Tayarani-Binazir</name><name sortKey="Zubair, Mohammed" sort="Zubair, Mohammed" uniqKey="Zubair M" first="Mohammed" last="Zubair">Mohammed Zubair</name></country><country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Psychologie/explor/DanceTherParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000355 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000355 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Psychologie
|area= DanceTherParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:3A0D5F157B0A593D17D43EB7E889F5189630C0AD
|texte= Antiparkinsonian activity of L‐propyl‐L‐leucyl‐glycinamide or melanocyte‐inhibiting factor in MPTP‐treated common marmosets
}}
| This area was generated with Dilib version V0.6.35. |  |